JP2017516775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516775A5 JP2017516775A5 JP2016568918A JP2016568918A JP2017516775A5 JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5 JP 2016568918 A JP2016568918 A JP 2016568918A JP 2016568918 A JP2016568918 A JP 2016568918A JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- treatment
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 6
- 230000000340 anti-metabolite Effects 0.000 claims 6
- 229940100197 antimetabolite Drugs 0.000 claims 6
- 239000002256 antimetabolite Substances 0.000 claims 6
- 238000009175 antibody therapy Methods 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MKLKAQMPKHNQPR-NSHDSACASA-N C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O Chemical compound C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O MKLKAQMPKHNQPR-NSHDSACASA-N 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096807A JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462002366P | 2014-05-23 | 2014-05-23 | |
| US62/002,366 | 2014-05-23 | ||
| US201562150004P | 2015-04-20 | 2015-04-20 | |
| US62/150,004 | 2015-04-20 | ||
| PCT/US2015/031931 WO2015179615A1 (en) | 2014-05-23 | 2015-05-21 | Combination therapies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Division JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516775A JP2017516775A (ja) | 2017-06-22 |
| JP2017516775A5 true JP2017516775A5 (esLanguage) | 2018-06-28 |
| JP6787792B2 JP6787792B2 (ja) | 2020-11-18 |
Family
ID=53277114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568918A Active JP6787792B2 (ja) | 2014-05-23 | 2015-05-21 | がんの処置のための併用治療 |
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170182003A1 (esLanguage) |
| EP (2) | EP3134085B1 (esLanguage) |
| JP (2) | JP6787792B2 (esLanguage) |
| KR (1) | KR102535283B1 (esLanguage) |
| CN (2) | CN110354266A (esLanguage) |
| AU (1) | AU2015264102C1 (esLanguage) |
| CA (1) | CA2949961C (esLanguage) |
| IL (1) | IL249065A0 (esLanguage) |
| MA (1) | MA39906A (esLanguage) |
| MX (1) | MX393818B (esLanguage) |
| RU (1) | RU2708374C2 (esLanguage) |
| SG (1) | SG11201609770TA (esLanguage) |
| WO (1) | WO2015179615A1 (esLanguage) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR102473601B1 (ko) | 2016-07-07 | 2022-12-01 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크 포인트 저해약을 포함하여 이루어진 조합 |
| JP7198666B2 (ja) * | 2016-08-26 | 2023-01-04 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
| CN117402852A (zh) | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| TWI768043B (zh) | 2017-05-18 | 2022-06-21 | 瑞士商愛杜西亞製藥有限公司 | N-取代吲哚衍生物 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| KR102632028B1 (ko) | 2017-05-18 | 2024-01-31 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 페닐 유도체 |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| JP7159007B2 (ja) * | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CA3090485C (en) * | 2018-02-05 | 2024-01-16 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| CA3096546A1 (en) * | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020081979A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Low dose radiation conditioning for immunotherapy |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| SG11202103839UA (en) | 2018-10-31 | 2021-05-28 | Gilead Sciences Inc | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| ES2995259T3 (en) | 2019-01-22 | 2025-02-10 | Keythera Suzhou Pharmaceuticals Co Ltd | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020243390A1 (en) * | 2019-05-31 | 2020-12-03 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| JP2023503031A (ja) * | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| BR112022017382A2 (pt) * | 2020-03-04 | 2022-11-29 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário |
| KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| US20240409516A1 (en) * | 2021-01-28 | 2024-12-12 | Shenzhen Zhongge Biological Technology Co., Ltd. | Pyrazolamide derivative, preparation method therefor, and application thereof |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| JP2024520801A (ja) | 2021-06-11 | 2024-05-24 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| JP7654118B2 (ja) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20240368088A1 (en) * | 2021-09-03 | 2024-11-07 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Ep4 antagonist compound as well as salt, polymorph and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2548491A1 (en) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic anti-cancer compositions |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| AU2007283404B2 (en) * | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| KR101562580B1 (ko) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| BRPI0917592B1 (pt) | 2008-12-09 | 2021-08-17 | Genentech, Inc | Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição |
| BRPI1014174B8 (pt) * | 2009-04-22 | 2021-05-25 | Askat Inc | uso de um composto selecionado a partir de 4-((1s)-1-{[5-cloro-2-(4-fluorofenóxi)benzoil]amino}etil)ácido benzóico, 4-[(1s)-1-({[5-cloro-2-(3-fluorofenóxi)piridin-3-il]carbonil}amino)etil]ácido benzóico e 3-[2-(4-{2-etil-4,6-dimetil-1h-imidazo[4,5-c]piridin-1-il}fenil)etil]-1-[(4-metilbenzeno)sulfonil]urea para tratamento de um câncer epitelial relacionado à pge2 |
| CN102740887B (zh) | 2009-09-30 | 2015-04-15 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| PE20131343A1 (es) | 2010-09-21 | 2013-11-18 | Eisai Randd Man Co Ltd | Derivados de acido benzoico |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| KR102535283B1 (ko) | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
-
2015
- 2015-05-21 KR KR1020167035808A patent/KR102535283B1/ko active Active
- 2015-05-21 MX MX2016015363A patent/MX393818B/es unknown
- 2015-05-21 EP EP15726847.5A patent/EP3134085B1/en active Active
- 2015-05-21 SG SG11201609770TA patent/SG11201609770TA/en unknown
- 2015-05-21 RU RU2016150650A patent/RU2708374C2/ru active
- 2015-05-21 JP JP2016568918A patent/JP6787792B2/ja active Active
- 2015-05-21 AU AU2015264102A patent/AU2015264102C1/en active Active
- 2015-05-21 CN CN201910572217.2A patent/CN110354266A/zh active Pending
- 2015-05-21 WO PCT/US2015/031931 patent/WO2015179615A1/en not_active Ceased
- 2015-05-21 MA MA039906A patent/MA39906A/fr unknown
- 2015-05-21 EP EP25174070.0A patent/EP4656246A3/en active Pending
- 2015-05-21 CN CN201580039416.7A patent/CN106572993B/zh active Active
- 2015-05-21 US US15/312,980 patent/US20170182003A1/en not_active Abandoned
- 2015-05-21 CA CA2949961A patent/CA2949961C/en active Active
-
2016
- 2016-11-20 IL IL249065A patent/IL249065A0/en active IP Right Grant
-
2020
- 2020-06-03 JP JP2020096807A patent/JP7562296B2/ja active Active
-
2021
- 2021-11-17 US US17/528,510 patent/US11707448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A5 (esLanguage) | ||
| JP2016533366A5 (esLanguage) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2017517506A5 (esLanguage) | ||
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2016501221A5 (esLanguage) | ||
| JP2019532047A5 (esLanguage) | ||
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| JP2019523214A5 (esLanguage) | ||
| JP2018522858A5 (esLanguage) | ||
| JP2017510661A5 (esLanguage) | ||
| JP2015500225A5 (esLanguage) | ||
| JP2016536286A5 (esLanguage) | ||
| WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
| CY1116847T1 (el) | Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 | |
| MX2017010336A (es) | Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn. | |
| JP2018508512A5 (esLanguage) | ||
| JP2016528162A5 (esLanguage) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2019533651A5 (esLanguage) | ||
| MX385704B (es) | Derivado de heteroarilo o su sal farmacéuticamente aceptable, su método de preparación y composición farmacéutica para la prevención o tratamiento de enfermedades asociadas con pi3 cinasas que contiene el mismo como ingrediente activo. | |
| JP2015502926A5 (esLanguage) | ||
| JP2019511550A5 (esLanguage) |